Pulse Biosciences, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: Election of Directors: Darrin R. Uecker

Pulse Biosciences, Inc.’s own tally for this item (“Elect Director: Darrin R. Uecker”): 34,246,413 for, 779,036 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2027 Annual Meeting and until his or her successor is duly elected and qualified.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 610,857 for, 29,042 against.

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

Description as filed by funds: Election of Directors: Mahkam Zanganeh, D.D.S.

Pulse Biosciences, Inc.’s own tally for this item (“Elect Director: Mahkam Zanganeh, D.D.S.”): 34,241,938 for, 783,511 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2027 Annual Meeting and until his or her successor is duly elected and qualified.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 610,857 for, 29,042 against.

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

Description as filed by funds: Election of Directors: Manmeet S. Soni

Pulse Biosciences, Inc.’s own tally for this item (“Elect Director: Manmeet S. Soni”): 33,560,875 for, 1,464,574 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2027 Annual Meeting and until his or her successor is duly elected and qualified.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 132,623 for, 507,277 against.

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

Description as filed by funds: Election of Directors: Maria Sainz

Pulse Biosciences, Inc.’s own tally for this item (“Elect Director: Maria Sainz”): 35,007,101 for, 18,349 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2027 Annual Meeting and until his or her successor is duly elected and qualified.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 639,046 for, 853 against.

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

Description as filed by funds: Election of Directors: Paul A. LaViolette

Pulse Biosciences, Inc.’s own tally for this item (“Elect Director: Paul A. LaViolette”): 34,264,295 for, 759,401 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2027 Annual Meeting and until his or her successor is duly elected and qualified.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 611,277 for, 28,622 against.

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

Description as filed by funds: Election of Directors: Richard A. van den Broek

Pulse Biosciences, Inc.’s own tally for this item (“Elect Director: Richard A. van den Broek”): 34,278,978 for, 746,471 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2027 Annual Meeting and until his or her successor is duly elected and qualified.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 612,422 for, 27,477 against.

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

Description as filed by funds: Election of Directors: Robert W. Duggan

Pulse Biosciences, Inc.’s own tally for this item (“Elect Director: Robert W. Duggan”): 33,443,582 for, 1,583,174 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2027 Annual Meeting and until his or her successor is duly elected and qualified.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 610,664 for, 29,236 against.

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

Description as filed by funds: Election of Directors: Manmeet S. Soni

Pulse Biosciences, Inc.’s own tally for this item (“Elect Director: Manmeet S. Soni”): 52,867,085 for, 275,070 against, per its Form 8-K filed December 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2026 Annual Meeting and until his or her successor is duly elected and qualified.”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 423,921 for, 27,700 against, 11,530 abstained.

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

Description as filed by funds: Election of Directors: Richard A. van den Broek

Pulse Biosciences, Inc.’s own tally for this item (“Elect Director: Richard A. van den Broek”): 53,139,403 for, 28,316 against, per its Form 8-K filed December 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2026 Annual Meeting and until his or her successor is duly elected and qualified.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 33 asset managers below reported 456,257 for, 1,864 against.

Showing the 25 largest of 33 asset managers. See all 33 in the interactive database.

Description as filed by funds: Election of Directors: Robert W. Duggan

Pulse Biosciences, Inc.’s own tally for this item (“Elect Director: Robert W. Duggan”): 51,826,494 for, 1,329,627 against, per its Form 8-K filed December 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2026 Annual Meeting and until his or her successor is duly elected and qualified.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 408,809 for, 38,008 against, 11,530 abstained.

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.

Description as filed by funds: Election of Directors: Darrin R. Uecker

Pulse Biosciences, Inc.’s own tally for this item (“Elect Director: Darrin R. Uecker”): 52,633,945 for, 527,159 against, per its Form 8-K filed December 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2026 Annual Meeting and until his or her successor is duly elected and qualified.”
Support: 99.0% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 31 asset managers below reported 416,817 for, 37,030 against.

Showing the 25 largest of 31 asset managers. See all 31 in the interactive database.

Description as filed by funds: Election of Directors: Mahkam Zanganeh, D.D.S.

Pulse Biosciences, Inc.’s own tally for this item (“Elect Director: Mahkam Zanganeh, D.D.S.”): 52,650,407 for, 512,831 against, per its Form 8-K filed December 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2026 Annual Meeting and until his or her successor is duly elected and qualified.”
Support: 99.0% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 31 asset managers below reported 416,807 for, 37,040 against.

Showing the 25 largest of 31 asset managers. See all 31 in the interactive database.

Description as filed by funds: Election of Directors: Paul A. LaViolette

Pulse Biosciences, Inc.’s own tally for this item (“Elect Director: Paul A. LaViolette”): 52,661,322 for, 506,489 against, per its Form 8-K filed December 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2026 Annual Meeting and until his or her successor is duly elected and qualified.”
Support: 99.0% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 31 asset managers below reported 418,161 for, 35,712 against.

Showing the 25 largest of 31 asset managers. See all 31 in the interactive database.

Description as filed by funds: SUBJECT TO APPROVAL OF PROPOSAL 1, TO RATIFY THE GRANT UNDER THE PLAN OF (I) OPTIONS TO ACQUIRE UP TO 500,000 SHARES OF COMMON STOCK GRANTED TO CERTAIN COMPANY CONSULTANTS, AND (II) OPTIONS TO ACQUIRE UP TO 600,000 SHARES OF COMMON STOCK GRANTED TO CERTAIN COMPANY DIRECTORS.

The 33 asset managers below reported 12,996 for, 544,354 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 33 asset managers. See all 33 in the interactive database.

Description as filed by funds: To approve an amendment to the Pulse Biosciences, Inc. 2017 Equity Incentive Plan (the "Plan"), to increase the number of shares of the Company's common stock issuable under the Plan by 2,000,000 shares and to change the Plan's definition of "Consultant."

Pulse Biosciences, Inc.’s own tally for this item (“1. To approve an amendment to the Company's 2017 Equity Incentive Plan (the "Equity Plan") to increase the number of shares of the Company's common stock issuable under the Equity Plan by two million shares and to change”): 50,247,945 for, 2,753,901 against — passed, per its Form 8-K filed October 1, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Stockholders were asked to vote on the following items at the Special Meeting (the "Proposals"): Both Proposals were approved at the Special Meeting by the requisite vote of the Company's stockholders in accordance with the recommendation of the Company's Board of Directors.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 33 asset managers below reported 12,996 for, 544,354 against.

Showing the 25 largest of 33 asset managers. See all 33 in the interactive database.

Description as filed by funds: To approve, by non-binding advisory vote, the compensation of our named executive officers.

Pulse Biosciences, Inc.’s own tally for this item (“3. To approve, by non-binding advisory vote, the compensation of our named executive officers; and”): 52,270,567 for, 907,916 against, per its Form 8-K filed December 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 36 managers: 451,776 for, 11,566 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 102 managers: 1,077,595 for, 851,296 against, 500 not voted, 6,577 1 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To vote, on an advisory basis, the frequency of future advisory stockholder votes to approve the compensation of our named executive officers.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 36 managers: 13,664 for, 566,796 1 year. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 98 managers: 6,562 for, 15 against, 500 not voted, 1,859,137 1 year, 12,759 3 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

Pulse Biosciences, Inc.’s own tally for this item (“2. To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 45,976,355 for, 8,265 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: to ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026;”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 639,899 for.

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

Description as filed by funds: TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

Pulse Biosciences, Inc.’s own tally for this item (“2. To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”): 63,077,669 for, 53,963 against — passed, per its Form 8-K filed December 12, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 463,342 for.

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.